Deal links zero tariffs on medicines to a 25 percent NHS spending rise and NICE reforms, promising faster access and fresh investment, officials say
The United States and the United Kingdom struck a trade agreement that removes zero tariffs on medicines for UK-made drugs, ingredients, and medical technology, in exchange for a concrete pledge from the UK to pay more for new treatments. The arrangement ties tariff relief to a major change in how Britain values and buys medicines, and to the first significant rise in NHS drug spending in more than two decades.
What the deal includes
As described by US officials, the agreement will exempt UK-made pharmaceutical and medical products from so-called Section 232 sectoral tariffs and any future Section 301 country tariffs. In return, the UK has agreed to increase how much it pays for some medicines, committing that the state-run National Health Service, the NHS, will spend 25 percent more on treatments for at least the next three years.
The USTR released a statement, saying, “The United States and the United Kingdom announce this negotiated outcome pricing for innovative pharmaceuticals, which will help drive investment and innovation in both countries,” US Trade Representative Jamieson Greer said in a statement. The USTR statement said “the UK would increase the net price it pays for new medicines by 25 percent under the deal.”
Changes to NICE and pricing rules
Two sources familiar with the deal told Reuters that the package involves a major change to the value appraisal framework used by the National Institute for Health and Care Excellence, NICE, the body that decides whether new drugs are cost-effective for the NHS. NICE’s “quality-adjusted life year” measures the cost of a treatment for each healthy year it enables for a patient, with the upper threshold being 30,000 pounds ($39,789) per year. Alterations to that framework could raise the acceptable price for innovative therapies.
The USTR also noted a shift in the voluntary rebate system. “The office of the USTR said the UK had committed that the rebate rate would decrease to 15 percent in 2026.” The change reduces the proportion of sales drugmakers return to the NHS, which the industry has long argued would improve margins and encourage investment.
Industry reaction and investment promises
British ministers framed the deal as a boost for patients and the life sciences sector. British science and technology minister Liz Kendall said, “This vital deal will ensure UK patients get the cutting-edge medicines they need sooner, and our world-leading UK firms keep developing the treatments that can change lives,” Kendall said in a statement. She added that the agreement will help sustain and attract investment into the UK life sciences industry.
At least one global company highlighted planned investments tied to the deal. Reuters reported that the pharmaceutical giant’s CEO said it will be able to invest more than $500m over the next five years because of the deal. On Wall Street, market reactions were muted, with the report noting, “On Wall Street, the stock, which is traded under the ticker symbol BMY, is down by 0.1 percent. Other heavily affected pharmaceutical companies include AstraZeneca, which was down by about 1 percent, and GSK, down by 0.4 percent.”
Political context and next steps
Officials and analysts say the accord reflects long-running pressure from US leaders on European countries to pay more for American-developed medicines. As Reuters wrote, “US President Donald Trump has pressed the UK and the rest of Europe to pay more for US medicines, part of his push for their costs to be brought more in line with those paid in other wealthy nations.”
For the UK, the deal is presented as a trade-for-health bargain: tariff relief and greater market access in return for higher spending, altered appraisal rules, and a lower rebate rate. Supporters argue this will speed up patient access to new therapies and attract fresh research and manufacturing investment.
Critics in the pharmaceutical sector have previously said the UK operating environment is tough, and some firms have paused or cancelled UK investment, including major names such as AstraZeneca. The new arrangement aims to address some of those concerns, while striking a balance between keeping medicines affordable for the NHS and encouraging industry investment.
Implementation now turns on detailed technical changes to NICE’s valuation processes, the NHS’s procurement and budgeting, and how companies and government operationalize the rebate rate change. Observers will watch closely whether the promised 25 percent uplift in payments and the move to zero tariffs on medicines lead to faster approvals and more investment in UK life sciences, or whether disputes over value and access resurface as the pact is put into practice.
The agreement marks a notable moment in transatlantic trade and health policy, linking tariff policy directly to national drug spending, and testing whether targeted economic incentives can reshape where and how new medicines reach patients.
